Wealth Advisory Solutions LLC Decreases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Wealth Advisory Solutions LLC trimmed its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 25.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,114 shares of the company's stock after selling 6,679 shares during the period. Wealth Advisory Solutions LLC's holdings in Zoetis were worth $3,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of ZTS. Rakuten Securities Inc. increased its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC bought a new position in shares of Zoetis during the 4th quarter valued at approximately $30,000. Cornerstone Planning Group LLC increased its position in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Murphy & Mullick Capital Management Corp bought a new position in shares of Zoetis during the 4th quarter valued at approximately $44,000. Finally, Sound Income Strategies LLC increased its position in shares of Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after purchasing an additional 164 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Down 2.4%

Shares of ZTS stock traded down $3.89 during mid-day trading on Friday, hitting $154.91. The stock had a trading volume of 2,267,443 shares, compared to its average volume of 2,591,359. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33. The firm has a market capitalization of $68.97 billion, a P/E ratio of 27.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.91. The firm's 50-day moving average is $161.32 and its two-hundred day moving average is $161.86. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same period in the prior year, the business earned $1.38 EPS. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.29%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's dividend payout ratio is 35.91%.

Analyst Ratings Changes

Several research firms have recently weighed in on ZTS. Piper Sandler boosted their target price on Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Zoetis presently has an average rating of "Buy" and a consensus price target of $212.13.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares in the company, valued at approximately $2,571,930. This represents a 4.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.18% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.